产品名称：Stemgent/Fibroblast Growth Factor-basic (bFGF) | Cytokine/03-0002/50 μg

产品编号：03-0002

市场价：¥0.00

场地：美国(厂家直采)

产品分类：蛋白类>重组蛋白>细胞因子>

联系QQ：1570468124

电话号码：4000-520-616

邮箱： info@ebiomall.com

美元价：待定

品牌： Stemgent

公司：Stemgent, Inc

公司分类：

商品介绍

ProductOverview

FibroblastGrowthFactor-basic(bFGF),alsoknownasFGF-2,isaheparin-bindingmemberoftheFGFsuperfamilyofmolecules.Proteinsofthisfamilyplayacentralroleduringprenataldevelopmentandpostnatalgrowthandregenerationofavarietyoftissuesbypromotingcellularproliferationanddifferentiation.Additionally,bFGFisacriticalcomponentofembryonicstemcellculturemedium,allowingcellstoremaininanundifferentiatedstateinserum-freemedium^1,2.StemfactorbFGFisanapproximate17kDaproteinconsistingof155aminoacidresidues.

ProductSpecifications

Size

50μg

Source

E.coli

Formulation

Lyophilizedfrom5mMTris-HCl,pH7.5with150mMNaCl.

AminoAcidSequence

MAAGSITTLPALPEDGGSGAFPPGHFKDPKRLYCKNGGFFLRIHPDGRVDGVREKSDPHIKLQLQAEERGVVSIKGVCANRYLAMKEDGRLLASKCVTDECFFFERLESNNYNTYRSRKYTSWYVALKRTGQYKLGSKTGPGQKAILFLPMSAKS

UniprotAccessionNumber

P09038,residues1-155

Purity

Greaterthan95%bySDS-PAGEanalysis

EndotoxinLevel

Lessthan1.0EU/μgofbFGFasdeterminedbytheLALmethod.

BIOLOGicActivity

TheED₅₀is0.1to1ng/mlasdeterminedbythedosedependentproliferationofNIH3T3cells.

Sterility

TestedtobenegativeforMycoplasmasp.byPCRandmicrobialcontaminationbya sterilitytest.

StorageandStABIlity

StemfactorbFGFisshippedatroomtemperature.LyophilizedbFGFisstableforupto6monthsfromdateofreceiptwhenstoredat-20°Cto-80°C.ReconstitutedbFGF,atconcentrationsgreaterthanorequalto0.1mg/ml,isstableforupto3monthswhenstoredat-20°Candupto6monthswhenstoredat-80°C.

Reconstitution

CentrifugebrieflyandthenreconstitutebFGFin500μlof10mMTris,pH7.6,toyieldastocksolutionof0.1mg/mlofbFGF.Avoidfreeze-thawcyclesasitcanresultinlossofactivity.

SpecificationSheets

03-0002SpecificationsSheet

SafetyDataSheets

03-0002SafetyDataSheet

ApplicationNotes

bFGFSupportsHumanESCellSelf-Renewal

RelatedProducts

mRNAReprogrammingKit(00-0071)
microRNABoosterKit(00-0073)

References

Amit,M.,Carpenter,M.K.,Inokuma,M.S.,Chiu,C.P.,Harris,C.P.,Waknitz,M.A.,Itskovitz-Eldor,J.,andThompson,J.A.(2000)Clonallyderivedhumanembryonicstemcelllinesmaintainpluripotencyandproliferativepotentialforprolongedperiodsofculture.DevBiol227:271-278.
Xu,C.,Rosler,E.,Jiang,J.,Lebkowski,J.S.,Gold,J.D.,O’Sullivan,C.,Delavan-Boorsma,K.,Mok,M.,Bronstein,A.,andCarpenter,M.K.(2005)Basicfibroblastgrowthfactorsupportsundifferentiatedhumanembryonicstemcellgrowthwithoutconditionedmedium.StemCells23:315-323.
Vallier,L.,Alexander,M.,andPedersen,R.A.(2005)Activin/NodalandFGFpathwayscorporatetomaintainpluripotencyofhumanembryonicstemcells.J.CellSci.118:4495-4509.
Wang,G.,Zhang,H.,Zhao,Y.,Li,J.,Cai,J.,Wang,P.,Meng,S.,Feng,J.,Miao,C.,Ding,M.,Li,D.,andDeng,H.(2005)NogginandbFGFcooperatetomaintainthepluripotencyofhumanembryonicstemcellsintheabsenceoffeederlayers.BiochemBiophysResCommun330:934-942.
Greber,B.,Lehrach,H.,andAdjaye,J.(2007)Fibroblastgrowthfactor2modulatestransforminggrowthfactorbetasignalinginmouseembryonicfibroblastsandhumanESCs(hESCs)tosupporthESCself-renewal.StemCells25:455-464.

AdditionalPublications

MomcilovicO;SivapathamR;OronTR;MeyerM;MooneyS;RaoMA;ZengX."Derivation,characteriazation,andneuraldifferentiationofintegration-freeinducedpluripotentstemcelllinesfromParkinson"sdiseasepatientscfarryingSNCA,LRRK2,PARK2,andGBAmutations."PLoSONE11(5):e0154890.doi:10.1371/journal.pone.0154890(2016)
BhutaniK;NazorKL;WilliamsR;TranH;DaiH;DzakulaZZ;ChoEH;PangAWC;RoaM;CaoH;SchorckNJ;LoringJF."Whole-genomemutationalburdenanalysisofthreepluripotencyinductionmethods."NatureCommun7:10536(2016)
ZhuS;RussHA;WangX;ZhangM;MaT;XuT;TangS;HebrokM;DengS."Humanpancreaticbeta-likecellsconvertedfromfibroblasts."NatureCommun7:10080(2016)
ChiangP-M;WongPC."Differentiationofanembryonicstemcelltohemogenicendotheliumbydefinedfactors:Essentialroleofbonemorphogeneticprotein4."Development138:2833-2843(2011)
Wang,Y-C.,Nakagawa,M.,Garitaonandia,I.,Slavin,I.,Altun,G.,Lacharite,R.M.,Nazor,K.L.,Tran,H.T.,Lynch,C.,L.,Leonardo,T.R.,Liu,Y.,Peterson,S.E.,Laurent,L.,C.,Yamanaka,S.,Loring,J.F.(2011)SpecificlectinbioMarkersforisolationofhumanpluripotentstemcellsidentifiedthrougharray-basedglycomicanalysis.CellRes.21(11):1551-1563.

品牌介绍

Stemgent mRNA体细胞重编程系统

产品特点

1.快速 Fast

Stemgent® MicroRNA-Enhanced mRNA Reprogramming System只需2周即可将靶细胞重编程为iPS细胞，与仙台病毒（Sendai Virus）、非整合型DNA载体（Episomal DNA Vectors）等传统iPS重编程方法相比，缩短实验周期超过50%以上（Figure. 1）。

Figure 1. Stemgent® mRNA重编程系统、仙台病毒依赖的重编程系统以及游离型DNA载体依赖的重编程系统重编程时程比较。

简便 Easy

与病毒、DNA载体依赖的iPS重编程手段不同，使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System对靶细胞进行重编程，生成的iPS细胞无需进行复杂耗时的下游筛选程序，只需简简单单6个步骤，即可轻松构建iPS细胞系。

	Description	Day
Step 1	Material Preparation	Prior to starting
Step 2	Plate Cells	0
Step 3	Transfect Cells	1 to 12
Step 4	Identify Cells	13-14
Step 5	Pick and Passage iPS Cell Colonies	15-16
Step 6	Maintain iPS Cell Cultures	16+

注：因所用细胞类型及实验条件不同，上述时间轴可能略有不同，仅供参考。

Figure 2. Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程过程时间表、显微镜下观察到的重编程过程中靶细胞形态变化。第12天，形成的iPS克隆表达多能型Marker TRA-1-81。

高效 Efficient

病毒、DNA载体等依赖的iPS重编程技术，其重编程效率介于0.00001%到1%之间不等，而Stemgent® MicroRNA-Enhanced mRNA Reprogramming System的重编程效率远远大于1%，极大地提高了iPS克隆的产出率。

表1. 不同类型iPS重编程手段效率比较

Reprogramming Method	Efficiency	Integrating	Screening
RNA	>1%	No	No
仙台病毒（Sendai virus）	0.01-1%	No	Yes
DNA载体（Episomal/Minicircle）	0.00%	Possible	Yes
慢病毒（Lentivirus）	0.001-0.01%	Yes	Yes
腺病毒（Adenovirus）	0.0001-0.001%	Possible	Yes
Protein	0.00%	No	No

安全 Safe

某些iPS研究领域，例如iPS临床研究、治疗应用等，对iPS细胞的安全性提出了极高的要求。使用Stemgent® MicroRNA-Enhanced mRNA Reprogramming System重编程靶细胞，无需担心构建的iPS细胞系可能含有病毒载体残留，亦无需担心无关的基因整合进宿主基因组，是目前适用于临床研究及治疗的最理想选择。

而以仙台病毒（Sendai Virus）为载体的iPS重编程手段，其病毒基因组虽然不会整合进宿主染色体，仙台病毒本身也不具备复制能力，但是为了构建真正意义上的virus-free的iPS细胞系，通常需要经过一个10-20代、耗时费力的筛选过程，以确保最终得到的iPS细胞系无病毒载体残留。以慢病毒（Lentivirus）体的iPS重编程手段，病毒基因组能够永久整合进宿主基因组，会给后续的iPS细胞分析带来干扰。